MYX is a beaten up stock. Recent buying on good volumes is steadily driving the SP higher. The company reported a loss last year of $280M largely due to a write down of its generic drug business in the US. This appears to be a genuine one off and the company is otherwise profitable [revenue $525M EBITDA $116M]. It is generating growth in its branded products. Looks to be a recovering SP.
